Detailed Product Description

Dimebon is an orally active small molecule that has been shown to inhibitbrain cell death in preclinical studies of Alzheimer's disease and Huntington's disease,makingit a potential treatment for these and otherneurodegenerativediseases.Research suggests that it may also havecognition-enhancingeffects inhealthy individuals, in the absence of neurodegenerative disease pathology.


Recently Dimebon has attractedrenewed interest after beingshown to have positive effects on personssuffering from disease.

Patientswith mild to moderate Alzheimers disease who were taking  Dimebon, showed benefit in five criticalareas: memory, thinking, the ability to carry out activities of daily livinglike eating or dressing, behavior, and overall function. Improvements werenoted at six months and continued until the end of the 12-month, Phase 2 study,which was conducted in Russia.

In the current study, the authors noted that Dimebon is thefirst drug for Alzheimer's disease that continued to produce improvement inpatients over a 12-month period. Other approved drugs for Alzheimers, like Aricept, Exelon, Namenda and Razadyne, do not have this sustained effect, though researchers suggest that these drugs may slow progressionof the disease over many years.

Besides, Pfizer, Medivation IPAC found out,that Dimebon also helps from one more disease, destructing the cerebrum   Huntington's chorea. This disease is found in1000 times more rarely than Alzheimer`s Disease, but there no drugs from it yetat all.

 

Company LLC "Nauka Technika Medicina" has an exclusive permission from the open joint-stock company Organika in Novokuznetsk to sell Dimebon, which had passed through all the necessary certification procedures and is completely safe touse.

If you are interested in buying Dimebon, feel free to contact us and order it.